Mutual of America Capital Management LLC Grows Position in Merck & Co., Inc. (NYSE:MRK)

Mutual of America Capital Management LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 0.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 331,871 shares of the company’s stock after acquiring an additional 1,706 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Merck & Co., Inc. were worth $24,927,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRK. Ironwood Financial llc boosted its holdings in shares of Merck & Co., Inc. by 2.5% during the 3rd quarter. Ironwood Financial llc now owns 5,180 shares of the company’s stock valued at $389,000 after purchasing an additional 124 shares during the last quarter. Wealth Dimensions Group Ltd. lifted its position in shares of Merck & Co., Inc. by 0.9% in the third quarter. Wealth Dimensions Group Ltd. now owns 14,434 shares of the company’s stock worth $1,084,000 after buying an additional 125 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. lifted its position in shares of Merck & Co., Inc. by 0.7% in the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 18,152 shares of the company’s stock worth $1,363,000 after buying an additional 130 shares in the last quarter. Lenox Wealth Advisors LLC lifted its position in shares of Merck & Co., Inc. by 7.3% in the third quarter. Lenox Wealth Advisors LLC now owns 1,922 shares of the company’s stock worth $144,000 after buying an additional 131 shares in the last quarter. Finally, Oxler Private Wealth LLC lifted its position in shares of Merck & Co., Inc. by 1.8% in the second quarter. Oxler Private Wealth LLC now owns 7,332 shares of the company’s stock worth $570,000 after buying an additional 132 shares in the last quarter. Institutional investors own 71.43% of the company’s stock.

In other news, insider Kenneth C. Frazier sold 663,881 shares of the stock in a transaction on Tuesday, November 9th. The stock was sold at an average price of $82.26, for a total transaction of $54,610,851.06. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sanat Chattopadhyay sold 24,619 shares of the stock in a transaction on Friday, October 29th. The stock was sold at an average price of $87.32, for a total value of $2,149,731.08. The disclosure for this sale can be found here. Insiders have sold a total of 936,784 shares of company stock worth $78,682,559 in the last three months. Corporate insiders own 0.32% of the company’s stock.

MRK has been the topic of a number of research analyst reports. Barclays boosted their target price on Merck & Co., Inc. from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Monday, November 1st. Morgan Stanley decreased their target price on Merck & Co., Inc. from $88.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, November 29th. Mizuho initiated coverage on Merck & Co., Inc. in a research report on Thursday, December 23rd. They issued a “buy” rating and a $100.00 target price on the stock. Guggenheim lowered Merck & Co., Inc. from a “buy” rating to a “neutral” rating and set a $98.00 price objective for the company. in a research note on Tuesday, December 7th. Finally, Berenberg Bank reissued a “hold” rating and set a $92.00 target price (up previously from $86.00) on shares of Merck & Co., Inc. in a research report on Sunday, October 10th. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Buy” and a consensus price target of $91.65.

Merck & Co., Inc. stock traded down $0.19 during mid-day trading on Friday, hitting $81.13. The company’s stock had a trading volume of 269,711 shares, compared to its average volume of 11,512,449. The company has a 50 day moving average of $78.27 and a 200-day moving average of $77.98. The stock has a market cap of $204.93 billion, a PE ratio of 28.63, a P/E/G ratio of 1.78 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.07 and a current ratio of 1.31. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $91.40.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Wednesday, October 27th. The company reported $1.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.55 by $0.20. The company had revenue of $13.15 billion for the quarter, compared to the consensus estimate of $12.32 billion. Merck & Co., Inc. had a return on equity of 48.21% and a net margin of 14.64%. Merck & Co., Inc.’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.74 EPS. On average, equities research analysts forecast that Merck & Co., Inc. will post 5.8 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, January 7th. Stockholders of record on Wednesday, December 15th were given a dividend of $0.69 per share. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.65. The ex-dividend date of this dividend was Tuesday, December 14th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.40%. Merck & Co., Inc.’s dividend payout ratio is presently 97.53%.

About Merck & Co., Inc.

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Recommended Story: Reverse Stock Split

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.